期刊
EUROPEAN HEART JOURNAL
卷 42, 期 23, 页码 2265-2269出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehab196
关键词
Transcatheter aortic valve implantation; Antithrombotic treatment
Transcatheter aortic valve implantation (TAVI) is an effective treatment for older patients with symptomatic severe aortic stenosis, and its indication has expanded to younger patients at lower risk. Despite a decrease in thromboembolic and bleeding complications after TAVI, these adverse events are still common. Recommendations for antithrombotic therapy in patients undergoing TAVI are mainly based on expert opinion, while recent studies and trials provide updated insights on antithrombotic treatment during and after the procedure.
Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI. [GRAPHICS] .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据